Savara Inc (SVRA)
4.03
+0.22
(+5.77%)
USD |
NASDAQ |
Jun 28, 16:00
4.025
0.00 (0.00%)
After-Hours: 20:00
Savara SG&A Expense (TTM): 17.94M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 17.94M |
December 31, 2023 | 15.67M |
September 30, 2023 | 14.06M |
June 30, 2023 | 12.29M |
March 31, 2023 | 11.94M |
December 31, 2022 | 10.93M |
September 30, 2022 | 10.71M |
June 30, 2022 | 11.73M |
March 31, 2022 | 11.93M |
December 31, 2021 | 12.35M |
September 30, 2021 | 12.12M |
June 30, 2021 | 14.10M |
March 31, 2021 | 14.06M |
December 31, 2020 | 14.26M |
September 30, 2020 | 14.77M |
June 30, 2020 | 12.21M |
March 31, 2020 | 13.30M |
December 31, 2019 | 13.08M |
September 30, 2019 | 13.04M |
June 30, 2019 | 13.37M |
March 31, 2019 | 11.65M |
December 31, 2018 | 10.66M |
September 30, 2018 | 10.07M |
June 30, 2018 | 8.412M |
March 31, 2018 | 11.01M |
Date | Value |
---|---|
December 31, 2017 | 10.98M |
September 30, 2017 | 9.175M |
June 30, 2017 | 8.691M |
March 31, 2017 | 4.211M |
December 31, 2016 | 5.31M |
September 30, 2016 | -2.353M |
June 30, 2016 | -0.895M |
March 31, 2016 | 0.907M |
December 31, 2015 | 1.65M |
September 30, 2015 | 10.84M |
June 30, 2015 | 10.84M |
March 31, 2015 | 10.80M |
December 31, 2014 | 9.488M |
September 30, 2014 | 9.238M |
June 30, 2014 | 8.941M |
March 31, 2014 | 8.671M |
December 31, 2013 | 8.518M |
September 30, 2013 | 8.158M |
June 30, 2013 | 7.816M |
March 31, 2013 | 7.587M |
December 31, 2012 | 7.519M |
September 30, 2012 | 7.543M |
June 30, 2012 | 7.708M |
March 31, 2012 | 8.891M |
December 31, 2011 | 8.420M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
10.71M
Minimum
Sep 2022
17.94M
Maximum
Mar 2024
13.19M
Average
13.06M
Median
SG&A Expense (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | 172.76M |
Aldeyra Therapeutics Inc | 10.98M |
Akero Therapeutics Inc | 33.41M |
89bio Inc | 32.60M |
Vigil Neuroscience Inc | 28.08M |